Impel NeuroPharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is TRUDHESA, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa for the treatment of OFF episodes in Parkinson's disease. Impel NeuroPharma, Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.
IPO Year: 2021
Exchange: NASDAQ
Website: Impelnp.com
Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00
Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00
Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv
3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i
SEATTLE, March 17, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, March 24, 2023, at 8:30 a.m. ET to report its fourth quarter and full year 2022 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the web
Trudhesa® nTRx Increased by 27% in Q3 2022 vs. Q2 2022 to 16.7k: Net Product Revenue Increased to $3.1 Million Trudhesa surpasses 5% of Acute Branded Prescriptions among prescribers in Q3 One Year After Launch Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update. "This quarter represents a milestone for Impel as we completed the first full year of
SEATTLE, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Monday, November 14, 2022, at 8:30 a.m. ET to report its third quarter 2022 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and acco
Trudhesa® TRx's Grew 48% in Q2 2022 to Over 13K: Net Product Revenue Increased 59% Over Q1 2022 to $2.8 Million Sales Force Expanded by 50% to Capitalize on Prescription Momentum and Market Opportunity Company Reiterated Prescription Guidance Range of 70-85K TRx's for 2022 Initiated Proof-of-Concept Study for INP105 in Autism Spectrum Disorder Impel to Host Investor Conference Call Today at 8:30 A.M. ET SEATTLE, Aug. 15, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the second quarter ended
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, August 15, 2022, at 8:30 a.m. ET to report its second quarter 2022 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelp
Trudhesa® Continues Strong Launch Trajectory with Q1 2022 TRx Growth of 111% vs. Q4 2021 Planned initiation of INP105 Proof-of-Concept Study for Autism Spectrum Disorder in 2Q 2022 Financing Agreement with Oaktree Capital Extends Cash Runway into 2024 Impel to Host Investor Conference Call Today at 8:30 A.M. ET SEATTLE, May 16, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate upda
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, with an initial focus on the central nervous system, today announced it will host a live webcast on Monday, May 16, 2022, at 8:30 a.m. ET to report its first quarter 2022 financial results and provide a business update. The conference call may be accessed by dialling 877-295-2648 (domestic) or 470-495-9487 (international) and referring to conference ID 2468863. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals websi
Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.
SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support
Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of
SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that
SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan
New Analysis Indicates No Drug-Drug Interactions (DDIs) of Clinical Concern are Predicted When Recommended Doses of Trudhesa and Gepants are Co-Administered Additional Analyses from the STOP 301 Trial Show Concomitant Use of Trudhesa with Triptans and Preventative CGRP, Erenumab, Were Well-Tolerated with Limited Treatment-Emergent Adverse Events Reported SEATTLE, April 26, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today presented results from the first-ever pharmacokinetic (PK) and pharmacodynamic (PD) evaluation of potential
SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv
SEATTLE, April 11, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, announced today that four Trudhesa® (dihydroergotamine mesylate) nasal spray (0.725 mg per spray) abstracts have been selected to be presented at the upcoming American Academy of Neurology (AAN) Annual Meeting taking place in Boston, MA, April 22-27, 2023. The Trudhesa posters to be presented are as follows: A Cross-Sectional Survey of Prevailing Opinions from Headache Specialists Regarding Status Migrainosus Management; (Poster 12-001; Session 11) Presenta
Cellarity, a life sciences company founded by Flagship Pioneering to transform the way medicines are discovered, announced today the appointments of John Leaman, M.D., M.B.A., as Chief Financial Officer (CFO), Cameron Trenor, M.D., as Vice President and Head of Translational Medicine, and Anjali Kumar, Ph.D., as Vice President, Head of Business Development. In addition, Parul Doshi, M.B.A., has been promoted to Chief Data Officer in recognition of her significant contribution to the development of Cellarity and her leadership in the implementation of an efficient and scalable data infrastructure to support Cellarity's unique approach to drug creation. Cellarity is fundamentally redesignin
Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i
Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer
EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
POS AM - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
8-K - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
8-K - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
25-NSE - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
8-K - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
8-K - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13D - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)
SC 13G - IMPEL NEUROPHARMA INC (0001445499) (Subject)
SC 13D - IMPEL NEUROPHARMA INC (0001445499) (Subject)
SC 13G - IMPEL NEUROPHARMA INC (0001445499) (Subject)
SC 13G - IMPEL NEUROPHARMA INC (0001445499) (Subject)
SC 13G - IMPEL NEUROPHARMA INC (0001445499) (Subject)